Sepas Haji Sobhani, M. M. Daei, S. Dodangeh, Majid Hajikarimi, Navid Mohammadi
{"title":"溶栓治疗后代谢综合征对急性心肌梗死患者的影响","authors":"Sepas Haji Sobhani, M. M. Daei, S. Dodangeh, Majid Hajikarimi, Navid Mohammadi","doi":"10.32598/jid.25.4.3","DOIUrl":null,"url":null,"abstract":"Background: Metabolic syndrome (MetS) comprises a group of conditions that happen together and increase the risk of heart disorders. MetS has known characteristic diagnostic criteria and is diagnosed through physical examination and blood tests. This syndrome is extremely prevalent in patients with acute myocardial infarction. We aimed to determine the prevalence of MetS and its relationship with myocardial infarction and response to treatment in patients suffering from acute myocardial infarction under fibrinolytic treatment. Methods: In this cross-sectional study, 145 patients with acute ST-elevation myocardial infarction (STEMI) were enrolled. They were referred to Bu-Ali Sina Hospital in Qazvin, Iran, between January 2018 and January 2019 and were candidates for thrombolytic therapy. The patients were divided into two groups with and without MetS according to the NCEP ATP III definition (the National Cholesterol Education Program-Adult Treatment Panel III). In each group, the ST resolution of more than 50% in electrocardiogram was evaluated 90 minutes after thrombolytic administration. In addition, angiographic information and left ventricular ejection fraction (LVEF) were compared between the two groups. Results: Overall, the prevalence of MetS was 57.2% in the study population. After treatment, ST-segment resolution of more than 50%, the number of involved coronary vessels, the thrombolysis in myocardial infarction flow grade, mean LVEF, and type of myocardial infarction were similar in both study groups. Conclusion: Our study indicates that MetS does not affect the response rate to thrombolytic treatment.","PeriodicalId":91544,"journal":{"name":"Journal of inflammatory bowel diseases & disorders","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Metabolic Syndrome in Patients With Acute Myocardial Infarction After Thrombolytic Therapy\",\"authors\":\"Sepas Haji Sobhani, M. M. Daei, S. Dodangeh, Majid Hajikarimi, Navid Mohammadi\",\"doi\":\"10.32598/jid.25.4.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Metabolic syndrome (MetS) comprises a group of conditions that happen together and increase the risk of heart disorders. MetS has known characteristic diagnostic criteria and is diagnosed through physical examination and blood tests. This syndrome is extremely prevalent in patients with acute myocardial infarction. We aimed to determine the prevalence of MetS and its relationship with myocardial infarction and response to treatment in patients suffering from acute myocardial infarction under fibrinolytic treatment. Methods: In this cross-sectional study, 145 patients with acute ST-elevation myocardial infarction (STEMI) were enrolled. They were referred to Bu-Ali Sina Hospital in Qazvin, Iran, between January 2018 and January 2019 and were candidates for thrombolytic therapy. The patients were divided into two groups with and without MetS according to the NCEP ATP III definition (the National Cholesterol Education Program-Adult Treatment Panel III). In each group, the ST resolution of more than 50% in electrocardiogram was evaluated 90 minutes after thrombolytic administration. In addition, angiographic information and left ventricular ejection fraction (LVEF) were compared between the two groups. Results: Overall, the prevalence of MetS was 57.2% in the study population. After treatment, ST-segment resolution of more than 50%, the number of involved coronary vessels, the thrombolysis in myocardial infarction flow grade, mean LVEF, and type of myocardial infarction were similar in both study groups. Conclusion: Our study indicates that MetS does not affect the response rate to thrombolytic treatment.\",\"PeriodicalId\":91544,\"journal\":{\"name\":\"Journal of inflammatory bowel diseases & disorders\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of inflammatory bowel diseases & disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32598/jid.25.4.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of inflammatory bowel diseases & disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/jid.25.4.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:代谢综合征(MetS)包括一组共同发生并增加心脏疾病风险的疾病。MetS有已知的特征性诊断标准,通过身体检查和血液检查来诊断。这种综合征在急性心肌梗死患者中极为普遍。我们的目的是确定急性心肌梗死患者在纤溶治疗下MetS的患病率及其与心肌梗死的关系和对治疗的反应。方法:在这项横断面研究中,纳入145例急性st段抬高型心肌梗死(STEMI)患者。在2018年1月至2019年1月期间,他们被转介到伊朗加兹温的Bu-Ali Sina医院,并成为溶栓治疗的候选人。根据NCEP ATP III(国家胆固醇教育计划-成人治疗小组III)的定义,将患者分为有和没有MetS的两组。在每组中,在溶栓给药后90分钟评估心电图ST分辨率超过50%。并比较两组血管造影信息及左室射血分数(LVEF)。结果:总体而言,研究人群中MetS的患病率为57.2%。治疗后,两组患者st段溶解率均大于50%,冠脉受累数、心肌梗死溶栓程度、血流等级、平均LVEF、心肌梗死类型相似。结论:我们的研究表明MetS不影响溶栓治疗的应答率。
Impact of Metabolic Syndrome in Patients With Acute Myocardial Infarction After Thrombolytic Therapy
Background: Metabolic syndrome (MetS) comprises a group of conditions that happen together and increase the risk of heart disorders. MetS has known characteristic diagnostic criteria and is diagnosed through physical examination and blood tests. This syndrome is extremely prevalent in patients with acute myocardial infarction. We aimed to determine the prevalence of MetS and its relationship with myocardial infarction and response to treatment in patients suffering from acute myocardial infarction under fibrinolytic treatment. Methods: In this cross-sectional study, 145 patients with acute ST-elevation myocardial infarction (STEMI) were enrolled. They were referred to Bu-Ali Sina Hospital in Qazvin, Iran, between January 2018 and January 2019 and were candidates for thrombolytic therapy. The patients were divided into two groups with and without MetS according to the NCEP ATP III definition (the National Cholesterol Education Program-Adult Treatment Panel III). In each group, the ST resolution of more than 50% in electrocardiogram was evaluated 90 minutes after thrombolytic administration. In addition, angiographic information and left ventricular ejection fraction (LVEF) were compared between the two groups. Results: Overall, the prevalence of MetS was 57.2% in the study population. After treatment, ST-segment resolution of more than 50%, the number of involved coronary vessels, the thrombolysis in myocardial infarction flow grade, mean LVEF, and type of myocardial infarction were similar in both study groups. Conclusion: Our study indicates that MetS does not affect the response rate to thrombolytic treatment.